• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA grants iStar Medical IDE for glaucoma implant pivotal trial

July 15, 2021 By Sean Whooley

MINIject iSTARiSTAR Medical announced today that the FDA granted investigational device exemption to start a pivotal trial with its MINIject implant.

Wavre, Belgium–based iStar’s MINIject minimally invasive implant for glaucoma surgery will be investigated in the STAR-V study, enrolling over 350 patients with primary open-angle glaucoma.

MINIject combines the porous structure of iSTAR’s proprietary STAR material with the power offered by the supraciliary space to enhance natural fluid outflow, reduce intraocular pressure and the need for medication while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.

MINIject is iSTAR Medical’s revolutionary MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.

According to a news release, STAR-V will evaluate MINIject’s efficacy by the mean reduction in eye pressure and by the proportion of patients achieving at least a 20% reduction in eye pressure.

iStar said the study will report on the safety and efficacy of MINIject alone in a procedure not combined with simultaneous cataract surgery. Key study findings will become available when all patients complete two years in the study, with follow-up to evaluate long-term benefits and tolerability with MINIject in the treatment of mild to moderate glaucoma.

“We are very pleased that the FDA has granted us approval to bring this innovative technology to North American patients suffering from primary open-angle glaucoma in the STAR-V trial,” iSTAR Medical CEO Michel Vanbrabant said in the release. “Results from clinical trials in over 130 patients in Europe, Asia and Latin America have consistently demonstrated that MINIject maintains a positive safety profile and delivers a significant reduction of pressure thanks to our proprietary STAR material and the power of the supraciliary space.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic Tagged With: FDA, iSTAR Medical

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS